Humacyte, Inc. (NASDAQ:HUMA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have earned an average rating of “Moderate Buy” from the eight research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $8.1429.

Several equities research analysts have commented on the stock. UBS Group reaffirmed a “buy” rating on shares of Humacyte in a report on Monday, December 1st. Wall Street Zen cut Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, December 21st. Benchmark lowered their target price on Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Humacyte in a report on Monday, December 1st. Finally, D. Boral Capital reiterated a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Thursday, February 19th.

Hedge Funds Weigh In On Humacyte

Several institutional investors have recently made changes to their positions in the company. Prudential Financial Inc. acquired a new position in shares of Humacyte in the 2nd quarter valued at $28,000. Financial Advisors Network Inc. acquired a new stake in Humacyte during the second quarter valued at $28,000. Valeo Financial Advisors LLC purchased a new position in Humacyte in the second quarter valued at $32,000. Truist Financial Corp purchased a new position in Humacyte in the third quarter valued at $28,000. Finally, Cerity Partners LLC acquired a new position in shares of Humacyte in the second quarter worth about $35,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Stock Up 1.8%

HUMA stock opened at $1.16 on Friday. The company has a market capitalization of $217.23 million, a P/E ratio of -5.04 and a beta of 1.89. Humacyte has a 12 month low of $0.88 and a 12 month high of $3.36. The firm’s fifty day simple moving average is $1.09 and its 200-day simple moving average is $1.32. The company has a debt-to-equity ratio of 2.97, a current ratio of 1.62 and a quick ratio of 0.90.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.